1. Home
  2. CERS

as 11-21-2024 10:32am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Technology

EDP Services

Nasdaq

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Founded: 1991 Country:
United States
United States
Employees: N/A City: CONCORD
Market Cap: 324.3M IPO Year: 1997
Target Price: $3.17 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.11 EPS Growth: N/A
52 Week Low/High: $1.38 - $2.59 Next Earning Date: 10-30-2024
Revenue: $176,229,000 Revenue Growth: 14.71%
Revenue Growth (this year): 26.47% Revenue Growth (next year): 11.48%

CERS Daily Stock ML Predictions

Stock Insider Trading Activity of Cerus Corporation (CERS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Green Kevin Dennis CERS Chief Financial Officer Sep 3 '24 Sell $2.17 82,657 $178,744.95 590,365

Share on Social Networks: